24th March 2021:
Impact of the COVID-19 Pandemic on the Global Dengue Situation

00:00 “Introduction” by Prof. Zulkifli Ismail, Chairperson

07:06 “COVID-19 and DENGUE in SINGAPORE” by Prof. Ng Lee Ching

29:12 “Dengue transmission during COVID-19 lockdown: the influence of human mobility in Sri Lanka” by Dr. Hasitha Tissera

54:02 “Closing Remarks” by Prof. Zulkifli Ismail & Panelists

20th January 2021:
Managing the Severely Ill Dengue Patient – Adults & Children

20th January 2021:
Q&A Discussion: Managing the Severely Ill Dengue Patient – Adults & Children

00:08 – “What’s the role of platelets transfusion in severe adult dengue with thrombocytopenia and what is the cutoff point of platelets to transfuse? Is there any role of steroids in managing myocarditis in dealing with dengue in adult patients?”

02:10 – “What is the role of CVP in assisting with fluid management for dengue shock syndrome (DSS) in children? What is the role of ECHO in looking at IVC collapsibility in assisting fluid replacement in DSS children?”

05:20 – “In severe liver involvement in children, is there any role of IV NAC, like in adults?”

08:36 – Closing Remarks by Prof Zulkifli Ismail

28th October 2020:
Randomised Trials of Wolbachia for Dengue Control – A Step Towards Elimination?

28th October 2020:
Q&A Discussion: Randomised Trials of Wolbachia for Dengue Control – A Step Towards Elimination? 

00:00 – Introduction to Panelists by Chairperson Prof. Ooi Eng Eong –
00:50 – Panelists’ first impression of Prof. Simmons’ findings –
04:18 Prof. Ooi: “What were the responses from the residents, local government and health officials of Yogyakarta, and what’s next?”
05:45 Prof. Ooi: “What are some of your impressions and how do you see the impact on ASEAN and other parts of the world?”
08:27 – A multi-part question from Prof. Ng Lee Ching, Environmental Health Insitutute, Singapore … –
11:39 Webinar participant: “What were the differences between the release strategy in Indonesia vis-a-vis in Vietnam that made the Indonesia release more successful?”
12:49 Webinar participant: “How did you convince local authorities and residents of Yogyakarta to get on board with the release of more mosquitoes into their environment?”
16:55 Webinar participant: “Was there a dengue outbreak in the city during the period when the trial was conducted?”
18:53 Webinar participant: “What is the future of arbovirus control? Should public health programs focus on one method or a set of them?”
23:06 Webinar participant: “Did you continue to educate residents on source reduction or allow residents to adopt less vigilant approach knowing that the Wolbachia mosquito will do the job? Are residents and premises owners like construction sites fined when mosquito breeding is detected in their premises?” 25:12 Webinar participant: “Did the dengue vaccine controversy pose any challenges to the carrying out of the study?”
25:38 Webinar participant: “How do you know that the eggs will hatch? How many hatched?”
26:02 Prof. Ooi: “Is there a need for bridging studies to determine the effectiveness of this program in different parts of the world?”
27:30 Webinar participant: “What is the status of decreasing vectorial capacity of albopictus by Wolbachia superinfection or other means?”
29:27 Webinar participant: “I saw that the mosquito population index has one peak a year. In Singapore we have seen 2 peaks in a year from our gravitrap surveillance network. Do you know what drives the mosquito population up and down?”
31:37 Webinar participant: “In raising your Wolbachia infected mosquito stocks, is there an alternative to human volunteers as a blood source?”
33:11 End of Discussion – Closing Remarks